Literature DB >> 30182211

Retroperitoneal fibrosis secondary to non-urology carcinomas: a clinical and outcome analysis of 97 cases.

T Chen1, L Tian2, D Fan3, F Wu3, J Lu4, S Ding5.   

Abstract

PURPOSE: Accumulated evidences have reminded us that since the prognosis of retroperitoneal fibrosis (RPF) secondary to non-urology carcinoma is poor it is essential to distinguish this condition from others. The objective of this study is to investigate the clinical features and outcomes of this infrequent but life-threatening disease.
METHODS: A total of 97 patients diagnosed with RPF secondary to non-urology carcinoma were enrolled in this retrospective study. The baseline information, history of carcinoma, clinical presentation, laboratory results, diagnosis, treatment and prognosis of the patients were collected and analyzed.
RESULTS: The mean age was 62.32 ± 11.22 years (range 31-85 years). It took 16.72 ± 7.11 days (range 3-34 days) for the patients with originally unexplained hydronephrosis to get a definite diagnosis of RPF secondary to non-urology carcinoma. Imaging-confirmed RPF [confirmed by computed tomography (CT) or magnetic resonance imaging (MRI)] was found in 91 patients. Fifty-seven patients were diagnosed with histological-confirmed malignant RPF. Sixty-six patients received surgical interventions. Cystoscopy and double J tube were performed in 68 cases (102 sides, 172 times) and was failed in 93 times (54.07%). Pyelostomy was performed in 72 patients (92 sides) without a single failure. Furthermore, eighty patients received chemotherapy and/or radiotherapy. The 6-month survival since RPF secondary to non-urology carcinoma was confirmed was 30%.
CONCLUSIONS: All patients with newly diagnosed unexplained hydronephrosis should undergo an age-appropriate carcinoma screening. The prognosis of RPF secondary to non-urology carcinoma was dismal. When dealing with hydronephrosis affecting renal function, pyelostomy instead of double J tube catheterization should be performed ahead of time.

Entities:  

Keywords:  Carcinoma; Hydronephrosis; Prognosis; Retroperitoneal fibrosis

Mesh:

Year:  2018        PMID: 30182211     DOI: 10.1007/s12094-018-1936-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  21 in total

Review 1.  The epidemiology of gastric cancer.

Authors:  Mary Beth Terry; Mia M Gaudet; Marilie D Gammon
Journal:  Semin Radiat Oncol       Date:  2002-04       Impact factor: 5.934

Review 2.  Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease.

Authors:  James R Stone
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

3.  Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial.

Authors:  Augusto Vaglio; Alessandra Palmisano; Federico Alberici; Umberto Maggiore; Stefania Ferretti; Rocco Cobelli; Francesco Ferrozzi; Domenico Corradi; Carlo Salvarani; Carlo Buzio
Journal:  Lancet       Date:  2011-07-04       Impact factor: 79.321

4.  Malignant obstructive uraemia.

Authors:  G D Chisholm; R Shackman
Journal:  Br J Urol       Date:  1968-12

5.  Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study.

Authors:  Peter G Rose; Shamshad Ali; Charles W Whitney; Rachelle Lanciano; Frederick B Stehman
Journal:  Gynecol Oncol       Date:  2010-02-24       Impact factor: 5.482

6.  Retroperitoneal fibrosis in a patient with gastric cancer manifested by lower extremity edema and hydrocele.

Authors:  Ryo Yokoyama; Ryunosuke Tazaki; Hideaki Morita; Hitoshi Nishitani; Shinpei Ariumi; Sho Osuga; Koichi Sohmiya; Tatsuji Kono; Yoshifumi Narumi; Motomu Tsuji; Nobukazu Ishizaka
Journal:  Intern Med       Date:  2012-08-15       Impact factor: 1.271

Review 7.  Retroperitoneal fibrosis.

Authors:  Augusto Vaglio; Carlo Salvarani; Carlo Buzio
Journal:  Lancet       Date:  2006-01-21       Impact factor: 79.321

8.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501.

Authors:  Takeshi Sano; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

Review 9.  [Hydronephrosis as the first manifestation of primary metastatic breast cancer].

Authors:  W Kuhn; W Loos; H Graeff
Journal:  Geburtshilfe Frauenheilkd       Date:  1994-05       Impact factor: 2.915

Review 10.  Non-operative management of retroperitoneal fibrosis.

Authors:  P M Higgins; D N Bennett-Jones; P F Naish; G M Aber
Journal:  Br J Surg       Date:  1988-06       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.